OmniAb (NASDAQ: OABI) lifts 2026 outlook after stronger Q1 results
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
OmniAb reported a much stronger first quarter of 2026, with revenue rising to $14.4 million from $4.2 million a year earlier, mainly on higher milestone revenue. Total GAAP costs and operating expenses were $22.3 million, roughly flat year over year, while non‑GAAP cash costs and operating expenses fell to $12.3 million from $14.7 million.
Net loss narrowed to $7.7 million, or $0.06 per share, compared with $18.2 million, or $0.17 per share, in the prior‑year quarter. OmniAb raised 2026 revenue guidance to $28–$33 million and now expects year‑end cash and cash equivalents of $33–$38 million, reflecting confidence in partner progress and its technology platform.
Positive
- Revenue growth and improved profitability metrics – Q1 2026 revenue reached $14.4 million, up from $4.2 million a year earlier, while net loss narrowed to $7.7 million from $18.2 million and non‑GAAP cash costs and operating expenses fell to $12.3 million from $14.7 million.
- Raised 2026 financial guidance and stronger cash outlook – OmniAb increased 2026 revenue guidance to a range of $28 million to $33 million and now expects year‑end cash and cash equivalents of $33 million to $38 million, higher than its prior $30 million to $35 million outlook.
Negative
- None.
Insights
Q1 revenue surged, losses narrowed, and OmniAb raised its 2026 outlook.
OmniAb’s Q1 2026 revenue jumped to $14.4 million from $4.2 million, mainly from milestone revenue, while non‑GAAP cash costs and operating expenses declined to $12.3 million. Net loss improved to $7.7 million from $18.2 million, indicating better operating leverage.
Management increased 2026 revenue guidance to $28–$33 million and now expects year‑end cash and cash equivalents of $33–$38 million. The company reported 107 active partners and 409 active programs as of March 31 2026, underscoring a broad pipeline that could support future milestone and royalty revenue.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q1 2026 revenue: $14.4 million
Q1 2025 revenue: $4.2 million
Q1 2026 net loss: $7.7 million; $0.06 per share
+5 more
8 metrics
Q1 2026 revenue
$14.4 million
Three months ended March 31, 2026; primarily milestone revenue
Q1 2025 revenue
$4.2 million
Three months ended March 31, 2025 baseline comparison
Q1 2026 net loss
$7.7 million; $0.06 per share
Three months ended March 31, 2026
Q1 2025 net loss
$18.2 million; $0.17 per share
Three months ended March 31, 2025 comparison
Q1 2026 cash costs and operating expenses
$12.3 million
Non-GAAP cash costs and operating expenses for Q1 2026
2026 revenue guidance
$28–$33 million
Updated full-year 2026 revenue range
2026 GAAP costs and operating expenses guidance
$83–$88 million
Forecast full-year 2026 GAAP costs and operating expenses
Year-end 2026 cash and cash equivalents guidance
$33–$38 million
Expected cash and cash equivalents at end of 2026
Key Terms
milestone revenue, non-GAAP financial measure, cash costs and operating expenses, effective tax rate, +1 more
5 terms
milestone revenue financial
"with the increase primarily related to milestone revenue"
non-GAAP financial measure financial
"This press release includes financial results ... and also actual and projected cash costs and operating expenses, which is a non-GAAP financial measure"
A non-GAAP financial measure is a way companies present their financial results that excludes certain expenses or income to show how they believe their core business is performing. It matters because it can give a clearer picture of how the company is really doing, but it can also be used to make results look better than they actually are.
cash costs and operating expenses financial
"Cash costs and operating expenses were $12.3 million for the first quarter of 2026"
effective tax rate financial
"The full-year 2026 effective tax rate is expected to be approximately 0%"
The effective tax rate is the percentage of a company's profits that it pays in taxes. It shows how much of its earnings go to taxes after all deductions and credits are considered. For investors, it indicates how much of the company's income is taken by taxes, impacting overall profitability and financial health.
Phase 3 trials technical
"plans to advance precemtabart tocentecan directly to Phase 3 trials in metastatic colorectal cancer"
Phase 3 trials are the large-scale stage of testing for a new medical treatment or vaccine where the goal is to confirm effectiveness, monitor side effects, and compare it to existing options across hundreds to thousands of people. For investors, these trials are like a final dress rehearsal: their success or failure is the most powerful signal of whether a product can win regulatory approval, reach the market, and support future revenue, so results often drive stock value sharply.
Earnings Snapshot
Revenue: $14.4 million · Guidance included
Q1 2026
Revenue
$14.4 million
Net loss
$7.7 million
Net loss per share
$0.06
GAAP costs and operating expenses
$22.3 million
Non-GAAP cash costs and operating expenses
$12.3 million
Guidance
For 2026, OmniAb expects revenue of $28–$33 million, GAAP costs and operating expenses of $83–$88 million, non-GAAP cash costs and operating expenses of $50–$55 million, and year-end cash and cash equivalents of $33–$38 million.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2026
(Exact Name of Registrant as Specified in Its Charter)
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | ||||
(510 ) 250-7800
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
The | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On May 7, 2026, OmniAb, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this report.
In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit No. | Description | ||||
99.1 | Press release dated May 7, 2026 | ||||
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OMNIAB, INC. | ||||||||
Date: May 7, 2026 | By: | /s/ Kurt Gustafson | ||||||
| Name: Kurt Gustafson | ||||||||
| Title: Executive Vice President, Finance and Chief Financial Officer (Principal Financial and Accounting Officer) | ||||||||
Exhibit 99.1
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
Conference Call Begins at 4:30 p.m. Eastern Time Today
EMERYVILLE, Calif. (May 7, 2026) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2026, provided operating and partner program updates, and increased 2026 financial guidance.
“OmniAb experienced strong momentum during the first quarter as multiple partnered programs advanced into later-stage clinical development, reinforcing the diversity and value of our portfolio. With a very strong start to the year, we are raising our 2026 revenue guidance,” stated Matt Foehr, Chief Executive Officer of OmniAb. “Continued progression of partner programs highlights the value of our technology platform and positions our business well for the future. Our innovation efforts continue to differentiate our platform as demonstrated by the launch of OmniUltra™ and our xPloration® partner access program.”
First Quarter 2026 Financial Results
Revenue for the first quarter of 2026 was $14.4 million, compared with $4.2 million for the same period in 2025, with the increase primarily related to milestone revenue.
Research and development expense was $9.6 million for the first quarter of 2026, compared with $12.6 million for the same period in 2025, with the decrease due to lower personnel expense, share-based compensation expense, and external expenses associated with legacy small molecule ion channel programs. General and administrative expense was $6.6 million for the first quarter of 2026, compared with $7.9 million for the same period in 2025, with the decrease primarily due to lower personnel expense, share-based compensation expense, and legal fees.
Amortization of intangibles increased to $6.0 million for the first quarter of 2026, compared with $3.2 million for the same period in 2025, primarily due to a $2.9 million non-cash impairment related to the discontinuation of certain legacy small-molecule ion channel programs.
Total costs and operating expenses were $22.3 million for the first quarter of 2026, compared with $23.0 million for the same period in 2025. Cash costs and operating expenses were $12.3 million for the first quarter of 2026, compared with $14.7 million for the same period in 2025 (see note regarding "Use of Non-GAAP Financial Measure" below for further discussion of this non-GAAP measure).
Net loss for the first quarter of 2026 was $7.7 million, or $0.06 per share, compared with a net loss of $18.2 million, or $0.17 per share, for the same period in 2025.
2026 Financial Guidance
OmniAb revises 2026 financial guidance and now expects revenue to be in the range of $28 million to $33 million, versus $25 million to $30 million previously, and costs and operating expenses to be in the range of $83 million to $88 million, versus $80 million to $85 million previously. Cash costs and operating expenses remain unchanged and are expected to be in the range of $50 million to $55
million (see note regarding "Use of Non-GAAP Financial Measure" below for further discussion of this non-GAAP measure). The Company now expects to end the year with cash and cash equivalents in the range of $33 million to $38 million, versus $30 million to $35 million previously. The full-year 2026 effective tax rate is expected to be approximately 0%.
First Quarter 2026 and Recent Business Highlights
During the first quarter of 2026, OmniAb entered into a new license agreement with Florida State University. As of March 31, 2026, the Company had 107 active partners and 409 active programs, including 32 OmniAb-derived programs in clinical development or being commercialized.
Business and partner highlights from the first quarter of 2026 and recent weeks included the following:
IMVT-1402 & batoclimab
•The potentially registrational trial with IMVT-1402 in difficult-to-treat rheumatoid arthritis is fully enrolled, with topline data expected in the second half of this year. Topline data from the proof-of-concept trial with IMVT-1402 in cutaneous lupus erythematosus is also expected in the second half of this year.
•Potentially registrational studies with IMVT-1402 in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease remain on track with topline data in GD and MG expected in 2027.
•Immunovant announced topline data from its two Phase 3 studies evaluating batoclimab as a treatment for active, moderate-to-severe thyroid eye disease and intends to review future plans for the development of batoclimab with its partner HanAll Biopharma Co. Immunovant remains focused on rapidly advancing the clinical development of IMVT-1402.
TEV- '408
•Teva Pharmaceuticals announced a funding agreement with Royalty Pharma of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody TEV-'408 for vitiligo.
•Topline results of the Phase 1b trial evaluating TEV-'408 for vitiligo are expected in the first half of this year. Topline results of the Phase 2a trial evaluating TEV-'408 for celiac disease are expected in the second half of this year.
Precemtabart tocentecan (M9140)
•At the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, pooled data on precemtabart tocentecan, a novel anti‑CEACAM5 antibody‑drug conjugate with a topoisomerase 1 inhibitor payload, from the PROCEADE-CRC-01 study in patients with metastatic colorectal cancer were presented that showed an objective response rate of 26.8% and median progression-free survival of 6.9 months. The overall safety profile was consistent with earlier data with no new or unexpected treatment-emergent adverse events.
•Merck KGaA indicated that based on Phase 1 data, it plans to advance precemtabart tocentecan directly to Phase 3 trials in metastatic colorectal cancer, with study initiation anticipated in the second or third quarter of 2026.
OmniAb expects that multiple partner programs will be highlighted at the ASCO Annual Meeting taking place May 29 - June 2, 2026.
Conference Call and Webcast
OmniAb management will host a conference call with accompanying slides today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss this announcement and answer questions. To participate via telephone, please dial (833) 461-5787 using the conference ID 563758100. Slides, as well as the live and replay webcast, are available at https://investors.omniab.com/investors/events-and-presentations/default.aspx.
About OmniAb®
OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B-cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.
For more information, please visit www.omniab.com.
Forward-Looking Statements
OmniAb cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” and similar expressions, are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: statements regarding the value of our portfolio and growth prospects of our business; the ability to add new partners and programs; the ability to maintain a disciplined cost structure; continuation of our innovation efforts and the expected value and performance of our technologies and the opportunities they may create, including OmniUltra; potential contributions to our business by our xPloration partner access program; scientific presentations and clinical and regulatory events of our partners and the timing thereof and their perspectives on and expectations for their product candidates; and our 2026 financial guidance. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future operating results and success is dependent on acceptance of our technology platform and technologies by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control
over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain; risks arising from changes in technology; the competitive environment in the life sciences and biotechnology platform market; risks associated with quality and timing in manufacturing our xPloration instruments and related consumables and our reliance on a limited number of third-party manufacturers and suppliers; our failure to maintain, protect and defend our intellectual property rights; difficulties with performance of third parties we will rely on for our business; government healthcare reform, legislative measures and regulatory developments in the United States and foreign countries; unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price; the potential impact of tariffs, trade policies, geopolitical instability and conflicts, inflation and interest rate changes; we may not achieve our financial guidance; our operating expenses may be higher than we anticipate, including if we decide to engage in activities not currently in our plan or if we face unexpected, or higher than anticipated, expenses; we may use our capital resources sooner than we expect; and other risks described in our prior press releases and filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Partner Information
The information in this press release regarding partnered products and programs comes from information publicly released by our partners.
Note Regarding Use of Non-GAAP Financial Measure
This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also actual and projected cash costs and operating expenses, which is a non-GAAP financial measure, adjusted to exclude share-based compensation, depreciation and amortization of intangibles. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, OmniAb believes the presentation of actual and projected non-GAAP cash costs and operating expenses, when viewed in conjunction with GAAP figures, provides investors with a more meaningful understanding of our operating performance. Cash costs and operating expense is not intended to be considered in isolation or as a substitute for costs and operating expenses. A reconciliation between actual and projected GAAP costs and operating expenses and non-GAAP costs and operating expenses is provided later in this press release.
| Contacts: | ||||||||
| OmniAb, Inc. | ||||||||
| investors@OmniAb.com | ||||||||
| X @OmniAbTech | ||||||||
| Alliance Advisors IR | ||||||||
| Yvonne Briggs | ||||||||
| ybriggs@allianceadvisors.com | ||||||||
| (310) 691-7100 | ||||||||
[Tables Follow]
OMNIAB, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
| March 31, 2026 | December 31, 2025 | ||||||||||
| (Unaudited) | |||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 29,046 | $ | 25,524 | |||||||
| Short-term investments | 20,026 | 28,501 | |||||||||
| Accounts receivable, net | 12,639 | 7,390 | |||||||||
| Prepaid expenses and other current assets | 3,414 | 3,926 | |||||||||
| Total current assets | 65,125 | 65,341 | |||||||||
| Intangible assets, net | 119,121 | 125,149 | |||||||||
| Goodwill | 83,979 | 83,979 | |||||||||
| Property and equipment, net | 9,021 | 9,428 | |||||||||
| Operating lease right-of-use assets | 15,049 | 15,545 | |||||||||
| Restricted cash | 560 | 560 | |||||||||
| Other long-term assets | 795 | 912 | |||||||||
| Total assets | $ | 293,650 | $ | 300,914 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 1,652 | $ | 1,879 | |||||||
| Accrued expenses and other current liabilities | 4,031 | 6,291 | |||||||||
| Current contingent liabilities | 1,002 | 1,044 | |||||||||
| Current deferred revenue | 2,941 | 3,161 | |||||||||
| Current operating lease liabilities | 3,940 | 3,879 | |||||||||
| Total current liabilities | 13,566 | 16,254 | |||||||||
| Long-term contingent liabilities | 37 | 315 | |||||||||
| Deferred income taxes, net | 1,227 | 785 | |||||||||
| Long-term operating lease liabilities | 15,730 | 16,455 | |||||||||
| Long-term deferred revenue | 369 | — | |||||||||
| Other long-term liabilities | 75 | 78 | |||||||||
| Total liabilities | 31,004 | 33,887 | |||||||||
| Stockholders' equity: | |||||||||||
Preferred stock, $0.0001 par value; 100,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — | |||||||||
Common stock, $0.0001 par value; 1,000,000,000 shares authorized at March 31, 2026 and December 31, 2025; 144,783,813 and 144,308,383 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 14 | 14 | |||||||||
| Additional paid-in capital | 436,520 | 433,180 | |||||||||
| Accumulated other comprehensive income (loss) | (2) | 12 | |||||||||
| Accumulated deficit | (173,886) | (166,179) | |||||||||
| Total stockholders’ equity | 262,646 | 267,027 | |||||||||
| Total liabilities and stockholders’ equity | $ | 293,650 | $ | 300,914 | |||||||
OMNIAB, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share data)
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Revenue: | |||||||||||
| License and milestone revenue | $ | 12,025 | $ | 2,021 | |||||||
| Service revenue | 2,107 | 1,903 | |||||||||
| xPloration revenue | 54 | 42 | |||||||||
| Royalty revenue | 241 | 188 | |||||||||
| Total revenue | 14,427 | 4,154 | |||||||||
| Costs and operating expenses: | |||||||||||
| Cost of xPloration revenue | 15 | 3 | |||||||||
| Research and development | 9,640 | 12,602 | |||||||||
| General and administrative | 6,619 | 7,915 | |||||||||
| Amortization of intangibles | 6,028 | 3,228 | |||||||||
| Other operating income, net | (46) | (750) | |||||||||
| Total costs and operating expenses | 22,256 | 22,998 | |||||||||
| Loss from operations | (7,829) | (18,844) | |||||||||
| Other income (expense), net: | |||||||||||
| Interest income | 487 | 537 | |||||||||
| Other income, net | 77 | 1 | |||||||||
| Total other income, net | 564 | 538 | |||||||||
| Loss before income taxes | (7,265) | (18,306) | |||||||||
| Income tax (expense) benefit | (442) | 106 | |||||||||
| Net loss | $ | (7,707) | $ | (18,200) | |||||||
| Net loss per share, basic and diluted | $ | (0.06) | $ | (0.17) | |||||||
| Weighted-average shares outstanding, basic and diluted | 128,245 | 105,622 | |||||||||
OMNIAB, INC.
RECONCILIATION OF GAAP COSTS AND OPERATING EXPENSES TO NON-GAAP CASH COSTS AND OPERATING EXPENSES
| Three Months Ended March 31, | |||||||||||
(in thousands) | 2026 | 2025 | |||||||||
Costs and operating expenses (GAAP) | $ | 22,256 | $ | 22,998 | |||||||
Less: Depreciation of property and equipment | 606 | 966 | |||||||||
Less: Amortization of intangible assets | 6,028 | 3,228 | |||||||||
Less: Share-based compensation | 3,340 | 4,144 | |||||||||
Cash costs and operating expenses (Non-GAAP) | $ | 12,282 | $ | 14,660 | |||||||
(in millions) | 2026 Forecast | ||||
Costs and operating expenses (GAAP) | $83 to $88 | ||||
| Less: Depreciation and amortization | 18 | ||||
| Less: Share-based compensation | 15 | ||||
Cash costs and operating expenses (Non-GAAP) | $50 to $55 | ||||
FAQ
How did OmniAb (OABI) perform financially in Q1 2026?
OmniAb reported Q1 2026 revenue of $14.4 million, up from $4.2 million a year earlier. Net loss improved to $7.7 million, or $0.06 per share, compared with a net loss of $18.2 million, or $0.17 per share, in Q1 2025.
What 2026 revenue guidance did OmniAb (OABI) provide?
OmniAb now expects 2026 revenue of $28 million to $33 million, compared with its prior guidance of $25 million to $30 million. This higher range reflects stronger partner progress and milestone expectations following a robust first quarter of 2026.
How is OmniAb managing its operating expenses in 2026?
For 2026, OmniAb guides GAAP costs and operating expenses to $83–$88 million, up from $80–$85 million previously, while maintaining projected non‑GAAP cash costs and operating expenses at $50–$55 million, reflecting continued focus on managing cash-based spending.
What is OmniAb’s expected year-end 2026 cash position?
OmniAb expects to end 2026 with $33 million to $38 million in cash and cash equivalents, higher than its prior outlook of $30 million to $35 million. This updated range incorporates its revised guidance for revenue and operating expenses.
How many partners and programs does OmniAb (OABI) have?
As of March 31, 2026, OmniAb reported 107 active partners and 409 active programs, including 32 OmniAb-derived programs in clinical development or being commercialized. This broad partnered portfolio underpins potential future milestone and royalty revenue.
What non-GAAP metric does OmniAb highlight for Q1 2026?
OmniAb highlights non‑GAAP cash costs and operating expenses, which exclude share‑based compensation, depreciation and amortization. For Q1 2026, this metric was $12.3 million, down from $14.7 million in Q1 2025, indicating lower underlying cash operating spend.